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Milan, ItalyObjectives This study sought to evaluate the impact of baseline activated clotting time (ACT)–guided
heparin administration on major bleeding after transfemoral transcatheter aortic valve implantation
(TAVI).
Background Bleeding after TAVI is frequent and associated with unfavorable prognosis. Proper
intraprocedural heparin dose administration may reduce the risk of potential overdosing in this frail
study group.
Methods Of the patients who underwent transfemoral TAVI in our center from November 1, 2007
to June 31, 2012, 362 were retrospectively analyzed. Because abnormally high baseline ACT values
were noted, heparin was administered at the operator’s discretion, according to baseline ACT (ACT-
guided, n ¼ 174) or patient’s body weight (non–ACT-guided, n ¼ 188). The primary study objective
was 30-day major bleeding as deﬁned by the Valve Academic Research Consortium criteria. Secondary
objectives were any life-threatening, and minor bleeding, and other Valve Academic Research
Consortium outcomes at 30 days.
Results Bleeding occurred in 167 (46.1%) patients; of these, 76 (21.0%) had major bleeding. The
ACT-guided group had a signiﬁcantly lower occurrence of major (7.5% vs. 33.5%, p < 0.001),
life-threatening (12.1% vs. 20.2%, p ¼ 0.04), and any bleeding (25.9% vs. 64.9%, p < 0.001). Conversely,
no differences were noted in the other study objectives. After adjustment for potential confounders,
the protective odds ratio for ACT-guided therapy on major bleeding was 6.4 (95% conﬁdence interval:
2.3 to 17.9; p < 0.001) at 30 days.
Conclusions In our experience, heparin administration according to baseline ACT was correlated with
a signiﬁcantly lower occurrence of major bleeding in transfemoral TAVI. This strategy might be a useful
tool in reducing bleeding in this high-risk study group. (J Am Coll Cardiol Intv 2014;7:140–51) ª 2014
by the American College of Cardiology FoundationFrom the *Interventional Cardiology Unit, San Raffaele Scientiﬁc Institute, Milan, Italy; yCardiothoracic Department, San Raffaele
Scientiﬁc Institute, Milan, Italy; and the zCardiology Department, San Raffaele Scientiﬁc Institute, Milan, Italy. Dr. Montorfano is
a proctor for Edwards Lifesciences. Dr. Maisano has received consulting fees from Medtronic, Abbott Vascular, St. Jude Medical,
and Valtech Cardio; has received royalties from Edwards Lifesciences; and is a cofounder of 4tech. Dr. Latib serves on the
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 2 , 2 0 1 4 Bernelli et al.
F E B R U A R Y 2 0 1 4 : 1 4 0 – 5 1 Baseline ACT-Guided Heparin Administration in TAVI
141Transcatheter aortic valve implantation (TAVI) has been Institute, Milan, Italy) were retrospectively analyzed. Pati-
demonstrated to be a valid therapeutic option for high-risk
patients with symptomatic severe aortic stenosis (AS) (1,2).
However, a wide range of potential complications might
mitigate the beneﬁcial effect of TAVI procedures. Particu-
larly, TAVI-related bleeding still remains an important
complication demanding careful consideration. Bleeding after
TAVI is relatively frequent, ranging from 22.8% to 77.0%,
and has been correlated with increased mortality (3–5). This
is of particular concern in the TAVI study group mainly
composed of elderly patients who are more prone to
bleeding. Furthermore, patients with severe AS may have
abnormalities in coagulation pathways as indicated by a
higher incidence of spontaneous bleeding (6). The presenceSee page 152
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VARC = Valve Academic
Research Consortiumof severe comorbidities in this patient group, and the large
sheath sizes required for arterial access are the main causes of
bleeding complications after TAVI procedures. However, a
common cause of bleeding in this study group might be rep-
resented by excessive intraprocedural anticoagulation therapy
with heparin. According to the most recent expert consensus
statement on TAVI, weight-based intravenous unfractionated
heparin (UFH) is the recommended adjunctive intraprocedural
antithrombotic therapy during TAVI with a suggested acti-
vated clotting time (ACT) >300 s throughout the procedure
(7). On the other hand, anACT target range of 250 to 300 s has
been reported in the published data (8). Nevertheless, to the
best of our knowledge, no study has speciﬁcally evaluated
appropriate heparin dosing in this clinical setting. Because
of the risk of potential overdosing with consequent hemor-
rhagic complications, strategies that provide a more accurate
heparin dosing need to be investigated.
In our clinical practice, we systematically collected base-
line ACT values during TAVI procedures, so we investi-
gated a strategy where baseline ACT values were used for
guiding subsequent heparin administration. Accordingly,
the aim of the present study was to evaluate the impact
of the baseline ACT-guided versus a non–ACT-based
“weight-adjusted” heparin administration strategy on
bleeding in transfemoral (TF) TAVI.Methods
Study population. From November 2007 to June 2012, all
consecutive patients with symptomatic severe AS treated
with TF-TAVI in our center (San Raffaele ScientiﬁcMedtronic Advisory Board; and has received consulting fees from Direct Flow
Medical. All other authors have reported that they have no relationships relevant to
the contents of this paper to disclose.
Manuscript received July 16, 2013; revised manuscript received October 20, 2013,
accepted October 24, 2013.ents were considered eligible for TAVI if they had a high
or prohibitive risk for conventional surgery after being
reviewed by a dedicated heart team, according to our current
practice previously reported (9,10).
Procedures and devices. Depending on clinical conditions and
evaluation of the patient by the cardiac anesthesiologist, the
procedurewas performed under either general or local anesthesia
with conscious sedation. Both self-expanding and balloon-
expandable prostheses were implanted. Initially, in November
2007, the Sapien THV (Edwards Lifesciences, Irvine, Califor-
nia) was used; the Medtronic CoreValve ReValving System
(Medtronic,Minneapolis,Minnesota) valves becameavailable in
July 2008, and the SapienXT replaced the SapienTHV inApril
2010 (10). Details of the procedure were previously reported
(9,10). In cases of full percutaneous TF approach, all therapeutic
femoral access sites were closed with the Prostar (Abbott
Vascular, Abbott Park, Illinois)
pre-closure device. Moreover, the
arterial access and closure of the
access sites were performed with a
“crossover technique” (11,12).
Heparin administration strategy:
ACTversusnon–ACT-guidedgroup.
As a standard practice used by
our cardiac anesthetists, a base-
line ACT measurement before
administering heparin was per-
formed in all patients undergoing
TAVI procedures. ACT samples
were drawn through the arterial
sheath immediately after the
insertion. To clear the sample
from the ﬂush solution contami-
nated by heparin, 10 ml of blood
was withdrawn before taking the
4-ml ACT sample. ACT was
measured using the Medtronic ACT Plus System.
Interestingly, we noticed abnormally high values of baseline
ACT in our study group. This observation raised the aware-
ness of some operators who have started to administer the
dosage of heparin on the basis of the baseline ACT values.
Accordingly, on the basis of the operator’s decision, in our
series, 2 heparin administration strategies were performed: 1)
an ACT-guided strategy in which heparin was adapted ac-
cording to the baseline ACT; and 2) a non–ACT-guided
strategy in which the heparin dosing was weight-adjusted.
Details regarding the 2 heparin administration strategies
are illustrated in Figure 1.
In both groups, the intraprocedural anticoagulant effect
of the UFH was monitored and subsequently adjusted to
maintain the ACT between 200 and 300 s. Heparin anti-
coagulation was reversed with protamine at neutralizing
doses, if necessary, according to operator’s preference.
Figure 1. Intraprocedural Heparin Administration Strategies in the Study Group
A baseline activated clotting time (ACT) measurement before heparin administration was systematically performed in all transfemoral transcatheter aortic valve
implantation procedures. According to the operator’s decision, 2 heparin administration strategies were performed: 1) an ACT-guided strategy in which heparin was
given according to the baseline ACT; and 2) a non–ACT-guided strategy in which the dosage of heparin was weight-adjusted. UFH ¼ unfractionated heparin.
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142Adjunctive therapies. All patients received acetylsalicylic
acid 100 mg before the procedure and lifelong thereafter. A
300-mg loading dose of clopidogrel was administered the
day before the procedure followed by 75 mg daily for
6 months. With regard to patients on oral anticoagulation
therapy (OAT), this was interrupted at least 3 days prior
to the TAVI procedure. In this group of patients, when
necessary, subcutaneous low-molecular-weight heparin was
used and was interrupted at least 12 h prior to the procedure.
In patients with indication to OAT, dual antiplatelet ther-
apy at discharge was prescribed according to the bleeding
and thrombotic risk of each patient (13).
Study objectives and data collection. The primary study
objective was 30-day occurrence of major bleeding. Sec-
ondary study objectives were life-threatening, minor, and
any bleeding; need for red blood cell (RBC) transfusions;
and the other Valve Academic Research Consortium
(VARC) outcomes at 30 days.
Study objectives were deﬁned according to the VARC
criteria (3).
The deﬁnition of clinically meaningful bleeding was on
the basis of objective criteria, including an obvious source of
bleeding and number of RBC transfusions.
A clear distinction between procedural and non-proce-
dural-related blood loss as well as obvious and nonobvious
source of hemorrhagic events were taken into account indeﬁning bleeding complications. Furthermore, bleeding
and the need for RBC transfusion were classiﬁed as
intraprocedural, pre-discharge (i.e., during hospital stay),
and post-discharge (3,14).
Follow-up data on clinical status and medication were
prospectively collected in all patients at 30 days with addi-
tional review of the patients’ case notes to enable all events to
be conﬁrmed. All serious adverse events were adjudicated
independently by 2 interventional cardiologists and 1 cardiac
surgeon. All patients provided written informed consent.
Statistical analysis. Continuous variables are presented as
mean  SD or as median (interquartile range [IQR]),
and were compared using the Student unpaired t or Mann-
Whitney rank-sum tests, on the basis of appropriate testing
for a normal distribution. The normality assumption for
continuous variables was evaluated by the 1-sample Kol-
mogorov-Smirnov test. Categorical variables are presented
as frequencies and percents and were compared using the
chi-square test when appropriate (expected frequency >5);
otherwise the Fisher exact test was used. Univariate analysis
was performed for all variables listed in Table 1. To deter-
mine independent predictors of 30-day major bleeding,
variables with probability value 0.20 in the univariate
analysis were entered in the multivariate model. To decrease
the effect of selection bias and potential confounders on
major bleeding outcomes, the variables such as the operator’s
Table 1. Baseline Clinical and Procedural Characteristics in the Overall Study Population and in ACT Versus
Non–ACT-Guided Group
Overall
(n ¼ 362)
ACT-Guided Group
(n ¼ 174)
Non–ACT-Guided Group
(n ¼ 188) p Value
Age, yrs 79.9  7.5 79.7  6.6 80.2  8.2 0.48
Female 185 (51.1) 97 (55.7) 88 (46.8) 0.09
Weight, kg 72  13.9 72  14.0 72  14.0 0.83
BMI, kg/m2 26.5  4.8 26.7  5.0 26.3  4.6 0.48
BSA, m2 1.78  0.18 1.78  0.19 1.77  0.17 0.41
Hb, g/dl 11.7  1.7 11.6  1.7 11.9  1.6 0.09
Platelets at baseline,  109/l 196.3  64 194.6  63 197.8  69 0.65
Baseline creatinine, mg/dl 1.3  1.2 1.3  1.0 1.3  1.3 0.72
Baseline eGFR, ml/min 53.3 (37.9–69.1) 53.7 (37.2–69.6) 52.4 (38.6–69.1) 0.99
CAD 145 (40.1) 76 (43.7) 69 (36.7) 0.18
Dyslipidemia* 211 (58.3) 106 (60.9) 105 (55.9) 0.33
Hypertension 273 (75.4) 136 (78.2) 137 (72.9) 0.24
Diabetes mellitus 104 (28.7) 51 (29.3) 53 (28.2) 0.81
Previous MI 65 (18.0) 25 (14.4) 40 (21.3) 0.09
Previous PCI 68 (18.8) 35 (20.1) 33 (17.6) 0.53
Previous CABG 70 (19.3) 35 (20.1) 35 (18.6) 0.72
Cerebrovascular disease 48 (13.3) 17 (9.8) 31 (16.5) 0.07
Chronic warfarin therapy 45 (12.4) 22 (12.6) 23 (12.2) 0.91
Atrial ﬁbrillation 80 (22.1) 42 (24.1) 38 (20.2) 0.42
Baseline INR in OAT patients 2.22  0.56 2.21  0.49 2.23  0.51 0.68
Pre-procedural INR in OAT patients 1.30  0.24 1.30  0.24 1.3  0.25 0.75
COPD 107 (29.6) 54 (31.0) 53 (28.2) 0.55
Chronic kidney diseasey 109 (30.1) 58 (33.3) 51 (27.1) 0.19
Peripheral vascular disease 82 (22.7) 39 (22.4) 43 (22.9) 0.92
Severe pulmonary hypertension 64 (17.7) 26 (14.9) 38 (20.2) 0.23
Porcelain aorta 49 (13.5) 24 (13.8) 25 (13.3) 0.89
Standard EuroSCORE 10 (9–12) 10 (8–12) 10 (9–12) 0.55
Logistic EuroSCORE 18.8 (11.4–30.5) 18.2 (10.3–29.7) 19.3 (11.8–30.7) 0.44
STS score 5.5 (3.6–9.1) 5.4 (3.5–10.1) 5.5 (3.7–8.1) 0.44
Aortic valve area, cm2 0.88  1.6 0.85  0.8 0.9  2.0 0.83
Mean gradient, mm Hg 53.5  16.7 52.2  16.5 54.5  16.9 0.21
LVEF, % 51.9  12.9 51.9  13.0 51.8  12.9 0.92
LVEF <35% 53 (14.6) 24 (13.8) 29 (15.4) 0.66
NYHA functional class III/IV 244 (67.4) 115 (66.1) 129 (68.6) 0.61
Angina 107 (29.6) 58 (33.3) 49 (26.1) 0.13
Syncope 60 (16.6) 27 (15.5) 33 (17.6) 0.60
Valve-in-valve procedure 19 (5.2) 9 (5.2) 10 (5.3) 0.96
Sapien (Edwards) 223 (61.6) 105 (60.3) 118 (62.8) 0.64
CoreValve (Medtronic) 139 (38.4) 69 (39.7) 70 (37.2) 0.37
Percutaneous femoral access 353 (97.5) 172 (98.9) 181 (96.3) 0.12
Surgical femoral access 9 (2.5) 2 (1.1) 7 (3.7) 0.18
Conscious sedation 318 (87.4) 165 (87.9) 153 (81.4) 0.28
Values are mean  SD, n (%), or median (IQR). *Deﬁned as serum cholesterol >200 mg/dl. yChronic kidney disease was deﬁned as eGFR <60
ml/min by MDRD (Modiﬁcation of Diet in Renal Disease) formula.
BMI ¼ body mass index; BSA ¼ body surface area; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; COPD ¼ chronic
obstructive pulmonary disease; eGFR ¼ estimated glomerular ﬁltration rate; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation;
Hb ¼ hemoglobin; INR ¼ international normalized ratio; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; NYHA ¼ New York
Heart Association; OAT ¼ oral anticoagulation therapy; PCI ¼ percutaneous coronary intervention; STS ¼ Society of Thoracic Surgeons.
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143decision in choosing the heparin administration strategy
and the learning effect (the cohort was divided into tertiles
according to procedural date to adjust for experience inTAVI accrued over time), were included in the logistic
regression analysis. Moreover, to account for the confoun-
ding effect between ACT versus non–ACT-guidance groups
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144and major bleeding, a propensity analysis, using a non-
parsimonious logistic regression model including all variables
listed in Table 1, was constructed. The score
was incorporated in the model; its calibration and discrimi-
nation were assessed by the goodness of ﬁt with the Hosmer-
Lemeshow and C-statistics, respectively. Results are
presented as odds ratio (OR) with 95% conﬁdence intervals
(CIs). For all analyses, a 2-sided p< 0.05 indicated statistical
signiﬁcance.
Statistical analysis was performed using the Statistical
Package for Social Sciences (version 20.0, SPSS, Inc.,
Chicago, Illinois).
Results
The patient ﬂow chart is illustrated in Figure 2. A total
of 362 patients underwent TF-TAVI during the studyFigure 2. Study Flow Diagram
Among 436 patients who underwent transcatheter aortic valve implantation (TAVI) i
heparin was administered according to 2 strategies: baseline activated clotting timeperiod. Baseline clinical and procedural characteristics of
the study group are summarized in Table 1. Overall, baseline
ACT values were 159.1  28.3 s. Of note, baseline ACT
175 s was present in the 30.4% of the patients.
Thirty-day VARC outcomes in the overall study group.
Bleeding occurred in 167 (46.1%) patients; of these, 76
(21.0%) had major bleeding. Fifty-nine (16.3%) and 32
(8.8%) patients had life-threatening and minor bleeding,
respectively. Interestingly, in 15.0%, the source of bleeding
was not obvious. Among 142 patients with obvious bleeding,
procedure-related bleeding occurred in 82.4% of cases.
Of these, 86.4% were secondary to major/minor vascular
complications and access site bleeding/hematoma not de-
ﬁned as major/minor vascular complications. Furthermore, a
signiﬁcant proportion of patients with an obvious source of
bleeding (17.6%) developed non-procedure-related hemor-
rhagic complications. In-hospital bleeding and theirn our center, 362 were treated with the transfemoral approach. Intraprocedural
(ACT) (ACT-guided) versus body weight (non–ACT-guided).
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145temporal relationships with the procedure are shown in
Figure 3. All bleeding events occurred during the index
hospital stay, mostly in the ﬁrst 24 h, with no registered cases
after discharge.
RBC transfusion was required in 140 (38.7%) patients.
The median number of transfused RBC packs was 2 (IQR:
2 to 4). The reasons for in-hospital RBC transfusion are
listed in Table 2. In the transfused patients, post-procedure
hemoglobin level was 8.4  0.93 g/dl. With regard to
timing, 31 (22.1%) patients were transfused during the
procedure and 109 (77.9%) patients during the index
hospital stay. Eleven patients required further RBC
transfusion after discharge in the absence of an obvious
bleeding source.
The other 30-day VARC outcomes are illustrated in
Table 3. Of note, patients who developed any bleeding had
a signiﬁcantly higher occurrence of 30-day all-cause mor-
tality (7.2% vs. 2.2%, p ¼ 0.04) as well as a trend toward
higher cardiovascular mortality (6.6% vs. 2.2%, p ¼ 0.05).
Moreover, in-hospital stay was longer in the bleeding pati-
ent cohort (7 [IQR: 5.75, 11.0] days vs. 6 [IQR: 5.0, 9.0]
days; p < 0.001).
The 30-day VARCoutcomesaccording toheparin administration
strategy: ACT vs. non–ACT-guided group. Baseline ACT
values were similar in the 2 groups (158.8  29.3 s in the
ACT-guided vs. 158.9  24.1 in the non–ACT-guided
group; p ¼ 0.89).
The choice of heparin administration strategy was fairly
balanced among the 4 operators involved, with 2 operators
more likely to choose the ACT-guided strategy and the
other 2 inclined to choose the non–ACT-guided strategy.Figure 3. Timing of Bleeding Following TF-TAVI
Temporal distribution of in-hospital bleeding with respect to the transcatheter aortic
TF ¼ transfemoral.Notably, in the ACT-guided group, a lower dose of total
heparin (4,000 international units [IU] [IQR: 3,375 to
5,000 IU] vs. 6,000 IU [IQR: 5,000 to 6,000 IU]; p <
0.001) was administered. In addition, in this group a lower
weight-adjusted heparin dose (IU/kg) (58.8 [IQR: 44.2 to
74.7] vs. 81.7 [IQR: 71.4 to 88.1]; p < 0.001) was given.
The mean intraprocedure post-heparin ACT in the ACT-
guided group was consequently lower than in the non–
ACT-guided group (238.4  58.9 s vs. 267.7  51.6 s; p <
0.001). Protamine was administered at neutralizing dose in
38 patients (20.2%) of the non–ACT-guided group and in
21 patients (12.1%) of the ACT group (p ¼ 0.80).
Notably, in the ACT-guided group a signiﬁcantly lower
occurrence of major bleeding (7.5% vs. 33.5%, p < 0.001),
as well as life-threatening (12.1% vs. 20.2%, p ¼ 0.04) and
any bleeding (25.9% vs. 64.9%, p < 0.001) was observed.
Figure 4 reports bleeding and transfusion need in the
ACT-guided versus non–ACT-guided groups.
Causes of overt bleeding in the 2 groups are illustrated
in Figure 5. Interestingly, the occurrence of access site
bleeding/hematoma not deﬁned as major/minor vascular
complications was signiﬁcantly lower in the ACT-guided
group than in the non–ACT-guided group (11.1% vs.
27.4%, p ¼ 0.03). Moreover, there was a trend toward a
lower incidence of non-procedure-related bleeding in the
ACT-guided group (13.9% vs. 17.0%, p ¼ 0.08). During
in-hospital stay, no adjunctive anticoagulation therapies
were required except in those who developed new-onset
atrial ﬁbrillation. However, administration of antico-
agulation therapy, which might partially account for a
higher rate of post-procedure bleeding, was similar invalve implantation (TAVI) procedure in the 142 patients with obvious bleeding.
Table 2. Causes of RCB Transfusion During the Index Hospital Stay
(N ¼ 140)
Procedure-related blood loss 88 (62.9)
Major vascular complications* 43 (48.9)
Minor vascular complications* 34 (38.6)
Hematoma/access site bleedingy 5 (5.7)
Cardiac tamponade 6 (6.8)
Non-procedural-related blood loss 52 (37.1)
Gastrointestinal bleeding 13 (25.0)
Genitourinary bleeding 3 (5.8)
Anemia 32 (61.5)
Unknown 4 (7.7)
Values are n (%). *Deﬁnitions on the basis of the Valve Academic Research Consortium criteria.
yNot deﬁned as major or minor vascular complications.
RBC ¼ red blood cell.
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146the 2 groups who developed atrial ﬁbrillation (12.8% in
ACT-guided vs. 11.5% in non–ACT-guided group,
p ¼ 0.49). Moreover, among 61 patients with an indi-
cation for OAT, 27.9% were discharged on OAT alone,
39.3% on OAT in combination with aspirin, and 32.8%
on OAT plus clopidogrel, with a similar proportion in the
2 groups.
However, other secondary outcomes did not signiﬁcantly
differ between the 2 groups (Table 3). Notably, despite the
fact that a lower heparin dose was administered in the ACT-
guided group, the rate of thrombotic complications was
similar in the 2 groups.Table 3. Thirty-Day VARC Outcomes in the Study Group an
Events
Overall
(n ¼ 362)
AC
Death
All-cause 16 (4.4)
Cardiovascular cause 15 (4.1)
Stroke 5 (1.4)
Minor stroke 3 (0.8)
Major stroke 2 (0.6)
TIA 4 (1.1)
Myocardial infarction 2 (0.6)
Aortic valve reintervention, any 14 (3.9)
Major vascular complications 54 (14.9)
Minor vascular complications 47 (13.0)
New permanent pacemaker implantation 3 (0.8)
Renal failure 106 (29.3)
AKI 1 58 (16.0)
AKI 2 20 (5.5)
AKI 3 28 (7.7)
Dialysis 18 (5.0)
Values are n (%). Deﬁnitions on the basis of the VARC criteria. The VARC
‘modiﬁed’ RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) c
ACT ¼ activated clotting time; AKI ¼ acute kidney injury; TIA ¼ transienLearning curve effect. A potential learning curve effect
across cases performed in the ﬁrst tertile of the study
period and those performed in the second and third tertiles
was noted for whole bleeding at 30 days. Time distribution
of bleeding is illustrated in Figure 6. Over the time course
of our TAVI experience, bleeding was signiﬁcantly
reduced because of smaller sheath size and the learning
curve effect.
A separate analysis was performed, excluding the cohort
of the ﬁrst 59 patients who had received heparin exclusively
on the basis of body weight, leading to a ﬁnal study group of
174 patients in the ACT-guided and 129 patients in non–
ACT-guided groups. As expected, the occurrence of life-
threatening bleeding was not statistically different between
the 2 groups (12.1% vs. 14.7%, p ¼ 0.49). However, there
remained a signiﬁcant difference in major bleeding (7.5% vs.
33.3%, p < 0.0001), as well as any bleeding (25.9% vs.
59.7%, p < 0.0001) and a trend toward a reduction in minor
bleeding (6.3% vs. 11.6%, p ¼ 0.07) in favor of the ACT-
guided group.
Predictors of major bleeding. Table 4 reports the variables
signiﬁcantly associated with 30-day major bleeding in uni-
variate and multivariate analyses. Operator preference in
heparin administration strategy was not found to have a
signiﬁcant effect in our series. Moreover, no correlation was
observed between major bleeding and sheath size nor be-
tween percutaneous versus surgical access closure and device
implanted. After adjustment for baseline confounders, the
absence of ACT guidance (OR: 5.89, 95% CI: 2.76 to 12.60;d in ACT Versus Non–ACT-Guided Group
T-Guided Group
(n ¼ 174)
Non–ACT-Guided Group
(n ¼ 188) p Value
7 (4.0) 9 (4.8) 0.77
7 (4.0) 8 (4.3) 0.95
2 (1.1) 3 (1.6) 1.00
1 (0.6) 2 (1.1) 0.11
1 (0.6) 1 (0.5) 0.75
0 (0.0) 4 (2.1) 0.13
0 (0.0) 2 (1.1) 0.50
7 (4.0) 7 (3.7) 0.87
24 (13.8) 30 (16.0) 0.56
24 (13.8) 23 (12.2) 0.66
0 (0.0) 3 (1.6) 0.55
45 (25.9) 61 (32.4) 0.20
24 (13.8) 34 (18.1) 0.18
9 (5.2) 11 (5.9) 0.81
13 (7.5) 15 (8.0) 0.89
9 (5.2) 9 (4.8) 0.85
deﬁnition includes the AKI deﬁnition based on the criteria from the
lassiﬁcation.
t ischemic attack; VARC ¼ Valve Academic Research Consortium.
Figure 4. 30-Day Bleeding in the ACT Versus Non–ACT-Guided Group
Bleeding occurrence according to the Valve Academic Research Consortium (VARC) outcomes is illustrated in the 2 groups. Outcomes were deﬁned according to
the VARC deﬁnitions. Any bleeding were deﬁned as composite of life-threatening, major and minor bleeding. ACT ¼ activated clotting time; RBC ¼ red blood
cell.
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147p < 0.001) and baseline estimated glomerular ﬁltration rate
(OR: 0.98, 95% CI: 0.97 to 1.00; p ¼ 0.04) were the only
predictors of 30-day major bleeding. Importantly, irre-
spective of the time the procedure was performed, the ACT-
guided strategy was associated with a signiﬁcantly lower
occurrence of major bleeding. Moreover, after multivariateFigure 5. Causes of Overt Bleeding in the ACT Versus Non–ACT-Guided Group
Causes of bleeding with an obvious source are depicted for each group. ACT ¼ actiadjustment for potential confounders ACT-guided pro-
pensity, absence of ACT guidance was identiﬁed as an in-
dependent predictor of major bleeding at 30 days (OR: 6.4,
95% CI: 2.3 to 17.9; p< 0.001). The C-statistic of 0.73 from
the model and the p value of 0.47 from the Hosmer-
Lemeshow goodness-of-ﬁt test indicate a good model ﬁt.vated clotting time.
Figure 6. Time Distribution of Bleeding According to the TAVI Experience
The incidence of overall bleeding according to the time distribution is illustrated. The study group was analyzed in tertile according to the TAVI experience. For each
tertile, the number of patients treated with the 2 strategies is reported. Abbreviations as in Figures 1 and 2.
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148Discussion
The present investigation provides 2 main novel ﬁndings. 1)
Baseline ACT levels were generally elevated in patients
with severe AS. 2) Compared with the non–ACT-guided
strategy, baseline ACT-guided heparin administration dur-
ing TAVI signiﬁcantly reduced the occurrence of major
bleeding, as well as any bleeding. In addition, ACT guid-
ance was found to be an independent predictor of major
bleeding events.
TAVI-related bleeding complications: incidence, prognostic
value, and potential mechanisms. The occurrence of
bleeding and the need for transfusion are still common and
remain an important issue in patients undergoing TAVI
with an increased risk of subsequent adverse outcomes.
Rates of major and life-threatening bleeding according toTable 4. Univariable and Multivariable Predictors of 30-Day Major
Bleeding After TF-TAVI
Variables
Univariable Multivariate
OR (95% CI) p Value OR (95% CI) p Value
Age 1.04 (1.00–1.08) 0.03 1.02 (0.98–1.07) 0.27
Lack of baseline ACT
guidance
6.24 (3.29–11.8) <0.001 5.89 (2.76–12.60) <0.001
Baseline eGFR* 0.96 (0.94–0.99) 0.03 0.98 (0.97–1.00) 0.04
BSA 0.20 (0.05–0.86) 0.03 0.37 (0.06–2.15) 0.27
Experience 0.63 (0.46–0.87) 0.04 0.68 (0.45–1.02) 0.06
*eGFR determined by MDRD (Modiﬁcation of Diet in Renal Disease) formula.
CI ¼ conﬁdence interval; OR ¼ odds ratio; TAVI ¼ transcatheter aortic valve implantation;
TF ¼ transfemoral; other abbreviations as in Tables 1 and 3.VARC deﬁnitions in the periprocedural period have been as
high as 15% to 32% and 5% to 16%, respectively (15). A
meta-analysis showed that any and major bleeding occurred
at a pooled estimate rate of 41.4% (95% CI: 35.5% to
47.6%) and 22.3% (95% CI: 17.8% to 28.3%), respectively
(4). This is in concordance with our experience, where we
observed major bleeding in 76 (21.0%) patients. In addi-
tion, 59 (16.3%) patients experienced life-threatening
bleeding, and 140 (38.7%) patients required RBC trans-
fusion during the index hospital stay. Bleeding has a strong
impact on prognosis in this study group. Indeed, the
published data has suggested the harmful impact of severe
bleeding and the need of RBC transfusion on short- and
long-term survival (2,4,5,15). Similarly, in our experience,
the occurrence of any bleeding was associated with a
signiﬁcantly higher 30-day overall mortality and a trend
toward higher cardiovascular mortality, as well as a longer
duration of hospital stay.
Several factors contribute to bleeding complications dur-
ing TAVI. The majority of bleeding during TAVI is
procedure-related. Indeed, the main cause is represented by
vascular/access site complications. The use of large delivery
catheters has been associated with a high rate of access site
complications, which may in turn be associated with sig-
niﬁcant, clinically overt bleeding. In addition, the presence
of diseased ilio-femoral axis in this old study group may
account for the increased vulnerability to vascular compli-
cations (15).
Another important factor contributing to vascular and
consequently to bleeding complications is represented by
the learning curve process. Decreasing the size of TAVI
delivery catheters has already been associated with
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149reduced vascular access site complications. In addition,
increased operator experience in the use of percutaneous
closure devices and the management of vascular compli-
cations have reduced the rate and impact of vascular
complications during TAVI (16). In accordance with
previous reports, there was also a learning curve effect
in our experience. Bleeding mainly related to vascular
complications has dramatically reduced over time because
of a smaller sheath proﬁle and an improved operator
experience.
Abnormalities of the coagulation pathways and risk for
bleeding in severe AS. Both aging and severe AS are
associated with an altered hemostatic state, leading to a
tendency toward increased bleeding. Indeed, the frail,
high-risk nature of these patients may increase the
vulnerability to develop bleeding during and after TAVI.
Moreover, abnormalities of coagulation pathways have
been described in patients with severe AS with a higher
incidence of spontaneous bleeding (6). The acquired type
2A von Willebrand syndrome has been advocated as the
cause of higher occurrence of spontaneous bleeding in these
patients.
Notably, the baseline ACT value in our TAVI study
group was 159.1  28.3 s. This value was higher than the
ACT value (129  26 s) of a historical group of patients
treated with percutaneous coronary intervention in our
center (17). Moreover, the baseline ACT in a cohort of
patients undergoing percutaneous coronary intervention for
stable coronary artery disease during the same study period
at our institution and who were pretreated with dual anti-
platelet therapy was 136.1  23.4 s.
Apart from the possible differences in the intrinsic
coagulation pathway and platelet function in patients with
AS, we could not ﬁnd any other reasons to explain why
these patients have a higher baseline ACT.
Furthermore, a signiﬁcant proportion of patients under-
going TAVI developed bleeding not directly related to
the procedure or received blood transfusions after the pro-
cedure despite having no obvious source of hemorrhage.
Généreux et al. (4) also reported that among the 25% of
patients who needed RBC after TAVI, 57% of the trans-
fusions given were not directly related to the procedure
(gastrointestinal/genitourinary bleeding, or no obvious
source). Similarly, despite the fact that the majority of
bleeding with an obvious source in our series was procedure-
related and was driven by access site/related bleeding,
accounting for 86.4% of the cases, about one-ﬁfth of our
study group experienced an obvious spontaneous bleeding
not directly procedure-related. Gastrointestinal, genitouri-
nary, and soft tissue bleeding were responsible for the ma-
jority of these non-procedure-related bleeding events during
the hospital stay. Moreover, procedure-related blood loss
requiring RBC transfusion was observed in only 88 (24.3%)
patients.Heparin administration according to baseline ACT-guided
strategy to reduce bleeding in TAVI patients. Another
important factor that may account for an increased vulner-
ability to bleeding in this study group is excessive anti-
coagulation therapy with heparin. TAVI requires an optimal
adjunctive periprocedural antithrombotic therapy. Vessel
injury itself, the introduction of catheters and wires during
endovascular procedures set off the coagulation cascade.
Furthermore, during TAVI, procedural embolic events may
occur during balloon valvuloplasty, manipulation of the
catheters across the aortic valve, and valve implantation (15).
Therefore, during TAVI, the thrombotic risk needs to be
carefully balanced with the bleeding hazard.
Administration of heparin according to body weight
and its monitoring by intraprocedural arterial ACT is the
method mostly used in percutaneous coronary intervention,
and this methodology has been adopted in all endovas-
cular procedures. Currently, heparin is the recommended
anticoagulation therapy during TAVI with a targeted ACT
ranging between 200 and 300 s throughout the procedure
(7,8). The cost and availability of a rapid “point of care” test
for dose adjustment as well as the presence of an antagonist
makes heparin a valid therapeutic option for this procedure.
The concept of an overdose of heparin in this study group
as the potential cause of bleeding has been recently perce-
ived by many TAVI centers. Although in the PARTNER
(Placement of Aortic Transcatheter Valves) trial, the intra-
procedural anticoagulation regimen was a UFH 5,000-IU
bolus weight-adjusted-based dose to keep ACT 250 s,
most TAVI centers moved toward a lower heparin dosing
ranging between 50 and 100 IU/kg (18). Similarly, in our
non–ACT-guided group, the median dose of UFH was
81.7 IU/kg.
Nonetheless, a simple weight-adjusted UFH administra-
tion does not take into account factors that may affect the
individual patient response to heparin, risking potential
overdosing in these particularly frail patients. The elderly
TAVI study group is generally more vulnerable to the
adverse effect of antithrombotic drugs, particularly bleeding.
Factors that may affect therapeutic agents (e.g., renal func-
tion, hepatic metabolism, body mass distribution) as well as
factors more speciﬁc to hemostasis (e.g., platelet dysfunc-
tion, coagulation disorders) may partially account for such
higher vulnerability to the side effects of antithrombotic
medications. Furthermore, the TAVI study group often
presents with impaired renal and liver function due to the
high prevalence of concomitant heart failure and is therefore
at risk of an exaggerated heparin response and prolonged
dose elimination.
Minimizing the bleeding risk correlated to a higher hep-
arin dose might be of utmost clinical relevance in this study
group. In the present study, we evaluated the added beneﬁt of
baseline ACT-guided heparin administration compared with
the standardized weight-adjusted antithrombotic treatment
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Importantly, despite the potential learning curve effect, the
baseline ACT-guided strategy allows a more accurate and
tailored heparin administration with a signiﬁcant reduction
in UFH dosing. This leads to a signiﬁcant reduction in 30-
day major and any bleeding during TF-TAVI. Our results
strongly suggest the existence of a possible relationship be-
tween bleeding and total/pro kilogram heparin dose as well as
intraprocedural ACT values during TAVI. In addition, we
observed a temporal relationship between the heparin
administration and bleeding. In fact, the majority (88.7%) of
bleeding occurred within the ﬁrst 24 h after the TAVI
procedure.
Notably, other important ﬁndings observed were: 1) a
signiﬁcantly lower occurrence (11.1% vs. 27.4%, p ¼ 0.03)
of hematoma/access site bleeding not deﬁned as major/mi-
nor vascular complications in the ACT-guided group; 2) a
trend toward lower incidence (13.9% vs. 17.0%, p ¼ 0.08)
of non-procedure-related bleeding in the ACT-guided
group; and 3) the absence of an increased rate of throm-
botic events in the ACT-guided group, despite the lower
dose of UFH administered.
Moreover, ACT guidance was shown to be a protective
factor against major bleeding that was independent from
the learning curve effect and operator’s preference of heparin
administration strategy.
Alternative anticoagulant therapies. Currently, alternative
anticoagulation regimens are under investigation in the
setting of TAVI. The role of bivalirudin versus heparin in
TF-TAVI will be assessed in the randomized BRAVO 2/3
(Effect of BivaliRudin on Aortic Valve Intervention Out-
comes 2/3) study. Primary endpoints will be 48-h/hospital
discharge major bleeding, and net adverse clinical events
including 30-day major bleeding, death, myocardial infarc-
tion, and stroke. This randomized study will provide fur-
ther insight into the optimal anticoagulation regimen during
TF-TAVI.
Study limitations. The most important limitation of our
study is the nonrandomized comparison of 2 treatment
strategies, even if propensity regression adjustment was
used to overcome the potential confounders. Another
caveat is that the ACT-guided heparin administration was
given according to the operator’s discretion, and thus it was
not administered in a standardized fashion. Furthermore,
age, comorbidities, platelet function, and dual antiplatelet
therapy may have interfered with baseline ACT. Moreover,
there was no uniformity on protamine administration or
documentation on timing of arterial sheaths removal.
Therefore, we cannot exclude that potential selection bias
and unmeasured and residual confounders may have
affected the results. Finally, the low rate of stroke seen in
our group may have allowed lower procedural ACT levels.
Despite these considerations, this simple strategy on
the basis of baseline ACT collection to guide UHFdosing may beneﬁt the reduction in bleeding rate during
TF-TAVI.Conclusions
Bleeding remains a frequent complication after TAVI and is
associated with poor outcomes. In our study, baseline ACT-
guided strategy for heparin administration in TF-TAVI was
correlated with lower 30-day major and any bleeding. Our
ﬁndings suggest that baseline ACT might be an effective
tool in guiding heparin administration during TF-TAVI.
Further randomized studies are warranted to determine
whether heparin should be given according to baseline ACT
guidance and to conﬁrm the usefulness of this strategy in
reducing the bleeding in TAVI study group.
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